Schrödinger Co-Founds Tectora with $55M Series A, Contributes Two Immunology Programs
SDGR sits 83% above its 52-week low of $10.945.
Summary
Schrödinger co-founded Tectora Therapeutics with NEA and RA Capital, contributing two early-stage immunology/inflammation programs (SDGR-4594, SDGR-8139) in exchange for equity, milestones, and royalties. Tectora closed a $55M Series A from the two VCs. This follows Schrödinger's pattern of spinning out programs—Ajax (acquired by Lilly for up to $2.3B) and the BMS Bunsen collaboration—validating its platform. The deal adds a new potential value stream without upfront cash, but the programs are early-stage and milestone-dependent. Watch for Tectora's preclinical progress and any future financing or partnership announcements.
At the time of this announcement, SDGR was trading at $20.03 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $10.95 to $23.02. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: BusinessWire.